Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2019.09.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Strategies for Patients with Mitral Regurgitation: A Meta-Analysis of Randomized Controlled Trials.
J Pers Med
August 2025
Klinik für Herz- und Kreislauferkrankungen, TUM Klinkum Deutsches Herzzentrum, Technische Universität München, 80636 Munich, Germany.
: Several treatment strategies are available for patients with mitral valve regurgitation (MR). However, evidence regarding their comparative effectiveness remains limited. We sought to compare the performance of different treatment strategies for personalized treatment of patients with MR.
View Article and Find Full Text PDFTranscatheter valve-in-valve mitral valve replacement with SAPIEN 3 valve for bioprosthetic mitral valve failure: one-year outcomes in 26 patients.
Zhejiang Da Xue Xue Bao Yi Xue Ban
August 2025
Department of Cardiovascular Surgery, Institute of Cardiovascular Surgery, West China Hospital, Sichuan University.
Objectives: To evaluate the one-year outcomes of valve-in-valve transcatheter mitral valve replacement (ViV-TMVR) using the SAPIEN 3 valve for treating mitral bioprosthetic valve failure.
Methods: A retrospective analysis was conducted on 26 patients with mitral bioprosthetic valve failure who underwent ViV-TMVR at West China Hospital, Sichuan University, between November 2022 and July 2024. The age of patients was 71.
Optimizing antithrombotic therapy following mitral valve repair: a comprehensive network meta-analysis.
BMC Cardiovasc Disord
August 2025
Department of cardiology, University hospital Rostock, Rostock, Germany.
Background: Mitral regurgitation (MR) presents either as primary or secondary, with options for surgical or transcatheter repair. Thromboembolic risks following surgery are significant despite the use of antithrombotic medications, and guidelines for postoperative anticoagulation therapy lack consistency. This systematic review aims to compare antithrombotic medications after mitral valve repair (MVR).
View Article and Find Full Text PDFEvolving Changes in Centre-Level Utilization of Longer Distance Donors in Heart Transplantation.
Interdiscip Cardiovasc Thorac Surg
August 2025
Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC 29425, United States.
Objectives: This study evaluates changes in centre-level utilization of longer distance donors (LDD) in heart transplantation (HT) before and after the allocation policy change in 2018.
Methods: Adult HT recipients from 2010 to 2023 were identified from the United Network for Organ Sharing registry. Patients were categorized based on donor centre distance and policy change.
The HighLife transcatheter mitral valve replacement system: A novel two-component platform.
Cardiovasc Revasc Med
August 2025
School of Medicine, European University Cyprus, Nicosia, Cyprus; 3(rd) Department of Cardiology, Euroclinic of Athens, Athens, Greece.
Mitral regurgitation (MR) remains a prevalent and undertreated condition, particularly in patients at high surgical risk or unsuitable for mitral transcatheter edge-to-edge repair (M-TEER). The HighLife (HighLife SAS, Paris, France) transcatheter mitral valve replacement (TMVR) system offers a novel solution with its unique two-component design comprising a subannular ring and a self-expanding bioprosthetic valve. Delivered via a transfemoral arterial and transseptal venous approach, this "valve-in-ring" system enables circumferential anchoring without the need for annular calcification or transapical access.
View Article and Find Full Text PDF